Astraveus

Executive Summary

Astraveus is a French biotechnology company founded in 2020 that aims to revolutionize cell therapy manufacturing with its integrated benchtop platform, Lakhesys – The Benchtop Cell Factory. By combining hardware, software, and consumables into a compact system, Astraveus simplifies the development and production of cell and gene therapies, making them more accessible from research through commercialization. The company addresses a critical bottleneck in the cell therapy space: the complexity and cost of manufacturing. Its all-in-one approach reduces the need for expensive infrastructure and specialized expertise, potentially accelerating time-to-clinic and lowering costs for developers. While still in its early stages, Astraveus has the potential to disrupt the cell therapy manufacturing market by democratizing production. The platform's compact footprint and integrated design could enable smaller biotechs and academic centers to develop therapies that were previously only feasible for large pharmaceutical companies. As the cell therapy market grows, Astraveus is well-positioned to capture value by providing a scalable, user-friendly solution. Key upcoming catalysts include fundraising milestones and initial commercial traction, which will validate the technology and drive adoption.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round70% success
• Q4 2026First Commercial Sale of Lakhesys60% success
• Q3 2026Strategic Partnership with Cell Therapy Developer50% success